Profound Medical Corp falls short on earnings expectations, casting a shadow over recent growth prospects.
On August 6, 2026, Profound Medical Corp (TSX: PRN) reported its second-quarter earnings, revealing an EPS of -$0.36, which missed analyst estimates of -$0.34 by 5.9%. This disappointing result comes despite a history of recent performance that has seen the company beat estimates in three of the last four quarters.
Recent earnings trend
Advertisement
Profound Medical Corp
PRN.TO
PRN.TO
Profound Medical Corp
WealthAwesomeAdvertisement
Market cap
$374.28M
52W high
$12.40
52W low
$5.23
1W change
-0.77%
Beta
0.53
Analyst Price Targets
Based on analyst covering PRN
Wall Street analysts forecast PRN stock price to rise 143.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.03
+143.0% Upside
Current Price
C$10.30
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PRN's historical volatility
30-Day Vol
60.6%
Annualized
90-Day Vol
53.9%
Annualized
Trend (90d)
+26.5%
Annualized drift
90d Mean
C$11.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.63 | C$8.62 – C$13.10 |
| 60 trading days | C$10.97 | C$8.16 – C$14.74 |
| 90 trading days | C$11.32 | C$7.88 – C$16.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 5 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-12 | — | -0.3300 | — |
| 2026-06-30 | 2026-08-06 | -0.3600 | -0.3400 | -5.9% |
| 2026-03-31 | 2026-05-07 | -0.2600 | -0.3500 | +25.7% |
| 2025-12-31 | 2026-03-05 | -0.3700 | -0.3800 | +2.6% |
| 2025-09-30 | 2025-11-13 | -0.3600 | -0.5200 | +30.8% |
| 2025-06-30 | 2025-08-14 | -0.7200 | -0.5500 | -30.9% |
Advertisement
Investor takeaway: While Profound Medical's recent earnings miss raises concerns, the company has a positive outlook among analysts, who see significant upside potential in their price targets. Investors should weigh the chances for recovery against ongoing operational challenges.
Bull case
Analysts are optimistic about Profound Medical's long-term growth, fueled by its innovative technologies in healthcare. The company's focus on robotic surgery and incisionless procedures positions it well for future market expansion.
Bear case
The recent earnings miss, along with the CAPTAIN trial not meeting its primary endpoint, may shake investor confidence and impact the company's growth momentum. Additionally, ongoing negative earnings could lead to more scrutiny from investors.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
